Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients

Abstract

Background The impact of diagnosis treatment and bronchial asthma on coronavirus disease 2019 (COVID-19) associated outcomes remains unclear. Objective To identify the prevalence and outcomes associated with asthma among hospitalized patients with COVID-19. Methods Electronic health records of 130 patients with asthma among hospitalized patients with COVID-19 were reviewed. Two subgroups of asthmatic patients were compared according to clinical outcomes during hospitalization. Patients with death results, intubation, and/or need of intensive care unit (ICU) stay were grouped as asthmatic patients with severe COVID-19 outcomes, and the rest were grouped as asthmatic patients with non-severe COVID-19 outcomes. Multivariable analyses were conducted with logistic regression to identify independent risk factors for severe outcomes. Results The prevalence of asthma in COVID-19 hospitalized patients was 5%. The mean age was 59.4 years and 54% were women. 17% received treatment in GINA step 4–5 asthma at the time of admission. An allergic asthma phenotype was determined in 38%. There was no significant difference in hospital length of stay or need for intubation between asthmatic patients and global COVID-19 admitted patients. 17% of asthmatic patients developed a severe outcome, and 5% had a death result. Elevated Lactate Dehydrogenase (LDH) level, low transcutaneous pulse oximetry (SpO2), the coexistence of atrial fibrillation (AF), and need for moderate or high ICS at admission were independent risk factors for a worse outcome in asthmatics COVID-19 hospitalized patients. Conclusion The prevalence of asthma in COVID-19 hospitalized patients was 5%, consistent with the asthma prevalence in the general population. The asthmatic patients with the previous prescription of moderate or high doses of ICS and/or coexistence of atrial fibrillation at admission had a higher risk of the severe outcome.

Long COVID Complicated by Fatal Cytomegalovirus and Aspergillus Infection of the Lungs: An Autopsy Case Report

“…In the presented case, immunohistochemistry did not uncover the SARS-CoV-2 virus in any other tissue except the lungs, which might represent a reservoir of the infection as well. Our patient suffered from bronchial asthma, a comorbidity with no increased risk for unfavorable outcomes of COVID-19 compared to the general population [ 18 ]. Long COVID, in turn, is considered an adverse prognostic factor in patients with bronchial asthma [ 19 ].…”

Effect of budesonide combined with montelukast sodium on pulmonary function parameters and immunoglobulin levels in children with bronchial asthma

“…Budesonide is one of the most widely used glucocorticoids. 20 It can effectively promote the efficacy of endogenous glucocorticoids, inhibit the inflammatory response in the respiratory tract of children, and then fully inhibit the activity of IgE. Hence, budesonide can achieve the dual efficacy of anti-allergy in the process of anti-inflammation.…”